Loading...

Repurposing the drug, ivermectin, in COVID-19: toxicological points of view

Shirazi, F. M ; Sharif University of Technology | 2022

282 Viewed
  1. Type of Document: Article
  2. DOI: 10.1186/s40001-022-00645-8
  3. Publisher: BioMed Central Ltd , 2022
  4. Abstract:
  5. The global COVID-19 pandemic has affected the world’s population by causing changes in behavior, such as social distancing, masking, restricting people’s movement, and evaluating existing medication as potential therapies. Many pre-existing medications such as tocilizumab, ivermectin, colchicine, interferon, and steroids have been evaluated for being repurposed to use for the treatment of COVID-19. None of these agents have been effective except for steroids and, to a lesser degree, tocilizumab. Ivermectin has been one of the suggested repurposed medications which exhibit an in vitro inhibitory activity on SARS-CoV-2 replication. The most recommended dose of ivermectin for the treatment of COVID-19 is 150–200 µg/kg twice daily. As ivermectin adoption for COVID-19 increased, the Food and Drug Administration (FDA) issued a warning on its use during the pandemic. However, the drug remains of interest to clinicians and has shown some promise in observational studies. This narrative reviews the toxicological profile and some potential therapeutic effects of ivermectin. Based on the current dose recommendation, ivermectin appears to be safe with minimum side effects. However, serious questions remain about the effectiveness of this drug in the treatment of patients with COVID-19. © 2022, The Author(s)
  6. Keywords:
  7. COVID-19 ; SARS-CoV-2 ; Angiotensin converting enzyme 2 ; Antivirus agent ; Asthenia ; Chemoprophylaxis ; Coronavirus disease 2019 ; Diarrhea ; Dizziness ; Drug efficacy ; Drug mechanism ; Drug metabolism ; Drug repositioning ; Drug safety ; Drug structure ; Drug tolerability ; Drug use ; Edema ; Headache ; Human ; In vitro study ; Nausea ; Nonhuman ; Pandemic ; Pharmacodynamics ; Rash ; Review ; Severe acute respiratory syndrome coronavirus 2 ; Toxicology ; Virostatic activity ; Virus inhibition ; Virus replication ; Vomiting ; Clinical trial (topic) ; Drug therapy ; Pre-exposure prophylaxis ; Procedures ; Antiviral agents ; Clinical trials as topic ; Humans ; Ivermectin
  8. Source: European Journal of Medical Research ; Volume 27, Issue 1 , 2022 ; 09492321 (ISSN)
  9. URL: https://pubmed.ncbi.nlm.nih.gov/35123559